ViiV's two-drug HIV treatment shows long-term efficacy.

At the 2020 HIV Conference in Glasgow, ViiV Healthcare published three years of data on the anti-HIV treatment of the Dorogway and Ramifedin two-drug program in Phase III GEMINI 1 and 2 clinical studies.
results showed that in adult AIDS patients who had not received HIV-1 treatment, the dologway-lamif-two-drug solution showed non-inferior, high genetic resistance and comparable safety compared to the dologway plus two nucleoside retrovirus inhibitors.
photo source: Confirmed virological withdrawal (CVW) was 1.7% of patients in both groups and 1.3% in the three-drug group, demonstrating the high resistance genetic barrier of Dorogway and Lamifding.
Globally, the number of people living with HIV over the age of 50 is increasing, demonstrating the success of antiretroviral therapy, which has gradually transformed HIV into a chronic disease," said Kimberly Smith, head of research and development at ViiV Healthcare.
" but longer HIV infection means patients need to take multiple medications for years.
as long as HIV is controlled, people living with HIV tend to take as few medications as possible.
"